Talis Biomedical Corporation specializes in molecular diagnostic tests that are designed for point-of-care testing, particularly for infectious diseases like COVID-19. Their main product, the Talis One COVID-19 Test System, allows healthcare providers to conduct tests and receive results directly at the location of care, such as hospitals and clinics. This system is capable of accurately detecting the SARS-CoV-2 virus and its variants, including Omicron. What sets Talis apart from its competitors is its focus on delivering lab-quality results quickly and conveniently, which helps healthcare providers make timely decisions regarding patient care. The company's goal is to enhance the accessibility and efficiency of diagnostic testing, ultimately improving patient outcomes and aiding in the management of infectious diseases.

CARB-X

Biotechnology

Healthcare

Talis Biomedical

REDWOOD CITY, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care (POC), today announced that it has appointed Dr. Andrew A. Lukowiak as president and chief scientific officer, effective August 1, 2023.Dr. Lukowiak has more than 20 years of senior leadership experience in the clinical diagnostics industry at both publicly traded and privately held commercial-stage companies. As a member of the executive leadership team, he will be responsible for leading the assay development, platform engineering, operations, regulatory and clinical affairs functions for Talis Biomedical.“We are thrilled to welcome Andrew to our leadership team as we continue to develop the Talis One® test menu and plan to initiate clinical studies to support our pursuit of multiple 510(k) clearances,” said Rob Kelley,” chief executive officer at Talis Biomedical

Talis Biomedical Announces Andrew Lukowiak, Ph.D., As President And Chief Scientific Officer (Cso)

Talis Biomedical is planning 103 job cuts in Redwood City.

Tech and Biotech Layoffs Rock Bay Area Job Market: Staff Cutbacks Widen

As well as to Western Digital's job cuts in Milpitas, Talis Biomedical is planning to cut 103 jobs in Redwood City due to the permanent closure of its laboratories and offices.

Tech and Biotech Layoffs Rock Bay Area Job Market as Staff Cutbacks Widen

In February 2021, Talis completed its IPO, selling 15,870,000 shares of common stock at a price of $16.00 per share.

Talis Biomedical went public on Feb 1st 21'.

Talis has not started its phased launch of the Talis One™ COVID-19 Test System due to challenges with manufacturing.

Talis Biomedical launches Talis One COVID-19 Test System

Pomerantz LLP announces that a class action lawsuit has been filed against Talis Biomedical Corporation (“Talis” or the “Company”) (NASDAQ: TLIS) and certain of its officers and directors.

Pomerantz LLP files suit against Talis

Practice Better announced that Kim Walsh will be stepping in as CEO and Nathalie Garcia, Co-Founder of Practice Better, will step into a new role as Chief Strategy Officer where she will continue serving Practice Better’s customers, employees, partners, and investors while supporting and advising Kim in her new role.HHAeXchange has appointed Paul Joiner as Chief Executive Officer. The new CEO’s appointment also further advances HHAeXchange’s commitment to innovation in its product roadmap and platform expansion, which will enable better technology in the home, improve care collaboration, and drive more efficient workflows.Intelerad Medical Systems™ announced the retirement of CEO Mike Lipps, who served the company for nearly three years as part of a 20-plus year software industry career, and is handing the organization’s global team and mission over to Mr. Jordan Bazinsky as the new Chief Executive Officer.Carteret Health appoints Kyle Marek as CEO after serving for more than five months as the hospital’s interim CEO.Cynerio appoints Rasu B. Shrestha, MD, MBA as Chairman of the Board for Cynerio. Dr. Shrestha brings extensive experience in healthcare innovation and commercialization to Cynerio, including spearheading a renewed focus on innovation at Advocate Health and launching new healthcare inventions, discoveries, and ideas to benefit patients and communities.Tegria, appoints Jen Morgan as its chief financial officer, and Prasanna Gunjikar as its chief growth officer. Atlas Healthcare Partners promotes Dan Jones to Chief Operating Officer and names Jessie Monnier as Market President to accelerate growth and leadership.CRISP Shared Services (CSS) names Marc Rabner, MD, MPH as its first-ever chief medical officer (CMO)

Recent Digital Health Executive Hires & Board Appointments

REDWOOD CITY, Calif., May 23, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced Heiner Dreismann has joined its board of directors, effective immediately. Talis Bio also recently appointed Kim Popovits, who has served as a member of the board since March 2020, as its lead independent director.“Heiner’s entrepreneurial vision and track record leading multiple corporate functions over the course of his 20-year tenure at Roche Diagnostics are ideal for the opportunities Talis Bio is pursuing,” said Rob Kelley, chief executive officer at Talis Bio. “We look forward to benefiting from Heiner’s seasoned perspective and Kim’s continued support as we execute our plan to deliver multiple women’s and sexual health tests at the point of care.”Dr. Dreismann has more than 35 years of experience in the diagnostic industry and is regarded as a pioneer in the early adoption of polymerase chain reaction (PCR) technique. From 1985 to 2006, he held multiple executive positions at Roche Diagnostics, including president and chief executive officer of Roche Molecular Systems, head of global business development of Roche Diagnostics and member of Roche’s Global Diagnostic Executive Committee. Dr

Talis Biomedical Appoints Former Roche Molecular Ceo Heiner Dreismann To Board Of Directors, Announces Former Genomic Health Ceo Kim Popovits As Lead Independent Director | Biospace

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Talis Biomedical Corporation (“Talis Biomedical” or the “Company”) (NASDAQ: TLIS) in the United States District Court for the Northern District of California on behalf of all persons and entities who purchased or otherwise acquired Talis Biomedical securities pursuant and/or traceable to the February 12, 2021 IPO.

Bragar Eagel & Squire PC filed suit against Talis Biomedical on Feb 12th 21'.

On November 15, 2021, Talis announced that Brian Blaser was appointed as President, Chief Executive Officer, and Director of Talis effective December 1, 2021.

Talis Biomedical hired Brian Blaser as President, Chief Executive Officer, and Director of Talis on Nov 15th 21'.

Molecular diagnostic tests for infectious diseases

Talis Biomedical

Molecular diagnostic tests for infectious diseases

Talis Biomedical

Molecular diagnostic tests for infectious diseases

About

Simplify's Take

What believers are saying

What critics are saying

What makes Talis Biomedical unique

6 month growth

1 year growth

2 year growth

Recently Posted Jobs

There are no jobs for Talis Biomedical right now.